Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early bactericidal activity of standard tuberculosis treatment
PACTR201209000394102Recruiting
- Sponsor
- Dr. Norbert Heinrich, Department fo Infectious Diseaes and Tropical Medicine, Klinium University of Munich (LMU)
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in pulmonary tuberculosis (TB), sponsored by Dr. Norbert Heinrich, Department fo Infectious Diseaes and Tropical Medicine, Klinium University of Munich (LMU). Primary endpoint: Decline in sputum bacillary counts over first 14 days. Started Dec 2010; status: recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201209000394102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201209000394102.